Immunotherapy for Infectious Diseases

320 Casadevall
52. Gallin JI, Malech HL, Weening RS, et al. A controlled trial of interferon gamma to prevent
infection in chronic granulomatous disease. N Engl J Med 1991; 324:509–516.
53. Phillips P, Forbes JC, Speert DP. Disseminated infection with Pseudallescheria boydii in
a patient with chronic granulomatous disease: response to gamma-interferon plus antifungal
therapy. Pediatr Infect Dis J 1991; 10:536–539.
54. Casadevall A. Antibody immunity and invasive fungal infections. Infect Immun 1995;
63:4211–4218.
55. Neely AN, Holder IA. Effects of immunoglobulin G and low-dose amphotericin B on
Candida albicans infections in burned mice. Antimicrob Agents Chemother 1992;
36:643–646.
56. Stratta RJ, Schaefer MS, Cushing KA, et al. A randomized prospective trial of acyclovir
and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy.
Arch Surg 1992; 127:55–64.
57. Klaesson S, Ringden O, Ljungman P, Aschan J, Hagglung H, Winiarski J. Does high-dose
intravenous immune globulin treatment after bone marrow transplantation increase mortality
in veno-occlusive disease of the liver? Transplantation 1995; 60:1225–1230.
58. Gudding R, Lund A. Immunoprophylaxis of bovine dermatophytosis. Can J Vet 1996;
36:302–306.
59. Thitithanyanont A, Mendoza L, Chuansumrit A, et al. Use of an immunotherapeutic vaccine
to treat a life-threatening human arteritic infection caused by Pythium insidiosum.
Clin Infect Dis 1998; 27:1394–1400.
60. Kirkpatrick CH. Transfer factor. J Allergy Clin Immunol 1988; 81:803–813.
61. Kauffman CA, Shea MJ, Frame PT. Invasive fungal infections in patients with chronic
mucocutaneous candidiasis. Arch Intern Med 1981; 141:1076–1078.
62. Wilson GB, Fudenberg HH, Keller RH. Guidelines for immunotherapy of antigen-specific
defects with transfer factor. J Clin Lab Immunol 1984; 13:51–58.
63. Kirkpatrick CH, Rich RR, Bennett JE. Chronic mucocutaneous candidiasis: model-building
in cellular immunity. Ann Intern Med 1971; 74:955–978.
64. Graybill JR, Silva J Jr, Alford RH, Thor DE. Immunologic and clinical improvement of
progressive coccidioidomycosis following administration of transfer factor. Cell Immunol
1973; 8:120–135.
65. Smith GR, Griffin DE, Graybill JR. Chronic pulmonary histoplasmosis: improved lymphocyte
response with transfer factor. Ann Intern Med 1976; 84:708–710.
66. Allen R, Barter CE, Chachoua LL, Cleeve L, O’Connell JM, Daniel FJ. Disseminated cryptococcosis
after transurethral resection of the prostate. Aust NZ J Med 1982; 12:296–299.
67. Allphin AL, Strauss M, Abdul-Karim FW. Allergic fungal sinusitis: problems in diagnosis
and treatment. Laryngoscope 1991; 101:815–820.
68. Folker RJ, Marple BF, Mabry RL, Mabry CS. Treatment of allergic fungal sinusitis: a
comparison trial of postoperative immunotherapy with specific fungal antigens. Laryngoscope
1998; 108:1623–1627.
69. Mabry RL, Manning SC, Mabry CS. Immunotherapy in the treatment of allergic fungal
sinusitis. Otolaryngol Head Neck Surg 1997; 116:31–35.
70. Casadevall A, Scharff MD. “Serum therapy” revisited: animal models of infection and the
development of passive antibody therapy. Antimicrob Agents Chemother 1994;
38:1695–1702.
71. Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in
infectious diseases. Clin Infect Dis 1995; 21:150–161.
72. Gordon MA, Casadevall A. Serum therapy of cryptococcal meningitis. Clin Infect Dis
1995; 21:1477–1479.
73. Casadevall A, Cleare W, Feldmesser M, et al. Characterization of a murine monoclonal
antibody to Cryptocococcus neoformans polysaccharide that is a candidate for human
therapeutic studies. Antimicrob Agents Chemother 1998; 42:1437–1446.